Clinical Trials of a New Antitumor Polypeptide: Neocarzinostatin (NCS)

Abstract

Neocarzinostatin, a new polypeptide which had shown antitumor activity in animals, was given to 17 patients with advanced malignant tumors. Five of 17 patients showed objective regression of tumors and disappearance of clinical symptoms. On account of the limited clinical experiences, no assertion can be made as to the range of therapeutic indication or to the comparison of neocarzino-statin with other antitumor substances. These preliminary observations, however, justify further extensive therapeutic trials.